Strong Immune Response To New SiRNA Drugs In Development May Cause Toxic Side Effects Date: May 25, 2009 Source: Mary Ann Liebert, Inc./Genetic Engineering News ...

Oligo DNA design. The AS-ODN used was the reverse sequence of 20 bases of Rous sarcoma virus phosphoprotein p60 (src) gene (GenBank accession no. M84475), beginning from the first Met of v-src: 5 ...

Nomura believes the research has potential applications as siRNA drugs for diseases such as hereditary transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, primary ...